Uterine cancer five year survival rates range between 25% and 96% depending upon the stage of the cancer at diagnosis, the health of the woman, her response to treatment and the grade of the tumor (different from the stage). New uterine cancer research is both in the research stage and clinical trials to improve those numbers.
In the research stage scientists are searching for ways to stop the growth of tumors, the metastasis and how to kill the cells. During clinical trials scientists have found medications, drugs or chemicals that appear to do the work in the laboratory environment. After receiving permission to use these chemicals on humans from the U.S. Federal Government, permission from the hospital administration and funding from drug companies who will be manufacturing the medication these drugs then enter the clinical trial phase where they are tested on patients with uterine cancers.
The time period between research, clinical trial and release to the public can range from 5 to 15 years depending upon how quickly the research phase becomes successful and if the drug is successful without side effects that outweigh the benefits to the patient.
